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the drugs available for this purpose. A short revision of the 
literature about treatment of secondary osteoporosis due 
both to androgen deprivation therapy for prostate cancer 
and to aromatase inhibitors for breast cancer was also per-
formed. Also premenopausal females and males with osteo-
porosis are frequently seen in endocrine settings. Finally 
particular attention was paid to the tailoring of treatment as 
well as to its duration.
Abstract Treatment of osteoporosis is aimed to prevent 
fragility fractures and to stabilize or increase bone mineral 
density. Several drugs with different efficacy and safety 
profiles are available. The long-term therapeutic strat-
egy should be planned, and the initial treatment should be 
selected according to the individual site-specific fracture 
risk and the need to give the maximal protection when the 
fracture risk is highest (i.e. in the late life). The present 
consensus focused on the strategies for the treatment of 
postmenopausal osteoporosis taking into consideration all 
Electronic supplementary material The online version of this 
article (doi:10.1007/s40618-016-0434-8) contains supplementary 
material, which is available to authorized users.
 * R. Attanasio 
 roberto.serena@libero.it
 F. Vescini 
 vescini.fabio@aoud.sanita.fvg.it
 A. Balestrieri 
 abalestrieri@ausl-cesena.emr.it
 F. Bandeira 
 fbandeira@gmail.com
 S. Bonadonna 
 stefaniabonadonna@endocrinologo.eu
 V. Camozzi 
 valentina.camozzi@unipd.it
 S. Cassibba 
 scassibba@hpg23.it
 R. Cesareo 
 robertocesareo@libero.it
 I. Chiodini 
 iacopo.chiodini@policlinico.mi.it
 C. Maria Francucci 
 cmfrancucci@libero.it
 L. Gianotti 
 laura.gianotti@unito.it
 F. Grimaldi 
 grimaldi.franco@aoud.sanita.fvg.it
 R. Guglielmi 
 rinaldo.guglielmi@gmail.com
 B. Madeo 
 brunomadeo@hotmail.com
 C. Marcocci 
 claudio.marcocci@med.unipi.it
 A. Palermo 
 A.Palermo@unicampus.it
 A. Scillitani 
 alscill@tin.it
 E. Vignali 
 edda.vignali@tin.it
 V. Rochira 
 rochira.vincenzo@unimore.it
 M. Zini 
 michele.zini@asmn.re.it
808 J Endocrinol Invest (2016) 39:807–834
1 3
Keywords Osteoporosis · Fracture · Treatment · 
Bisphosphonates · Teriparatide · Strontium ranelate · 
Denosumab · SERMs · Adherence · Side effects · 
Non-responder · Male osteoporosis · Drug-induced 
osteoporosis · Androgen deprivation · Aromatase 
inhibitors · Length of therapy
Abbreviations
AACE  American Association of Clinical 
Endocrinologists
ADT  Androgen deprivation therapy
AFF  Atypical femoral fractures
AI  Aromatase inhibitors
BC  Breast cancer
BMD  Bone mineral density
BMI  Body mass index
BP  Bisphosphonate
BSAP  Bone-specific alkaline phosphatase
BTM  Bone turnover marker
CHD  Coronary heart disease
CI  Confidence interval
CTX  Collagen type I C-telopeptide
DeFRA  Derived fracture risk assessment tool
DEXA  Dual energy X-ray absorptiometry
ET  Estrogen therapy
EPT  Estrogen plus progestin therapy
FIT  Fracture intervention trial
FLEX  FIT long-term Extension
FN  Femoral neck
FRAX  Fracture risk assessment tool
GFR  Glomerular filtration rate
GIO  Glucocorticoid-induced osteoporosis
GnRH  Gonadotropin-releasing hormone
GRADE  Grading of recommendations, assessment, 
development, and evaluation
HIV  Human immunodeficiency virus
HT  Hormone therapy
IV  Intravenous
LoE  Level of evidence
LS  Lumbar spine
LSC  Least significant change
MPA  Medroxyprogesterone acetate
ONJ  Osteonecrosis of the jaw
OR  Odds ratio
P1NP  N-terminal propeptide of procollagen type 1
PMO  Postmenopausal osteoporosis
PTH  Parathyroid hormone
RANK  Receptor activator of nuclear factor kappa B
RANK-L  RANK ligand
RCT  Randomized controlled trial
RR  Relative risk
SD  Standard deviation
SERM  Selective estrogen receptor modulator
SrR  Strontium ranelate
SC  Subcutaneous
T  Testosterone
TH  Total hip
WHI  Women’s health initiative
WHO  World Health Organization
1 Endocrinology and Metabolic Disease Unit, Azienda 
Ospedaliero-Universitaria Santa Maria della Misericordia, 
P.le S.M. della Misericordia, 15, 33100 Udine, Italy
2 Endocrinology Service, Galeazzi Institute IRCCS, Milan, 
Italy
3 Unit of Endocrinology and Diabetology, Department 
of Internal Medicine, M. Bufalini Hospital, Cesena, Italy
4 Division of Endocrinology, Diabetes and Bone Diseases, 
Agamenon Magalhães Hospital, University of Pernambuco 
Medical School, Recife, Brazil
5 Istituto Auxologico Italiano, Milan, Italy
6 Unit of Endocrinology, Department of Medicine, University 
of Padova, Padua, Italy
7 Endocrinology and Diabetology, Papa Giovanni XXIII 
Hospital, Bergamo, Italy
8 Endocrinology, S. Maria Goretti Hospital, Latina, Italy
9 Department of Clinical Sciences and Community Health, 
University of Milan, Milan, Italy
10 Post Acute and Long Term Care Department, I.N.R.C.A., 
Ancona, Italy
11 San Pier Damiano Hospital, Villa Maria Group Care 
and Research, Faenza, Ravenna, Italy
12 Endocrinology and Metabolic Diseases, S. Croce e Carle 
Hospital, Cuneo, Italy
13 Endocrinology Unit, Regina Apostolorum Hospital, Albano 
Laziale, Rome, Italy
14 Integrated Department of Medicine, Endocrinology 
and Metabolism, Geriatrics, University of Modena 
and Reggio Emilia, Modena, Italy
15 Endocrine Unit 2, Department of Clinical and Experimental 
Medicine, University Hospital of Pisa, Pisa, Italy
16 Department of Endocrinology and Diabetes, University 
Campus Bio-Medico, Rome, Italy
17 Endocrinology, Casa Sollievo della Sofferenza IRCCS, San 
Giovanni Rotondo, Italy
18 Department of Clinical and Experimental Medicine, 
University Hospital of Pisa, Pisa, Italy
19 Unit of Endocrinology, Department of Biomedical, Metabolic 
and Neural Sciences, University of Modena and Reggio 
Emilia, Modena, Italy
20 Endocrinology Unit, Arcispedale S. Maria Nuova IRCCS, 
Reggio Emilia, Italy
809J Endocrinol Invest (2016) 39:807–834 
1 3
Table of contents According to the GRADE system, the evidence qual-
ity is categorized as high, moderate, low, or very low. 
High quality evidence is defined as consistent evidence 
from well-performed randomized controlled trials 
(RCT) or exceptionally strong evidence from unbiased 
observational studies. Moderate quality evidence is evi-
dence from RCTs with important limitations (inconsist-
ent results, methodological flaws, indirect or imprecise 
evidence), or unusually strong evidence from unbiased 
observational studies. Low-quality evidence derives from 
observational studies, from RCTs with serious flaws, 
or indirect evidence. Very low-quality evidence stems 
from unsystematic clinical observations or very indirect 
evidence.
The GRADE system classifies the strength of recom-
mendations into two grades (strong or weak). Strong rec-
ommendations (terminology: “we recommend”) mean that 
benefits clearly outweigh harms and burdens, or vice versa. 
Weak recommendations (terminology: “we suggest”) mean 
that the desirable effects of adherence to a recommendation 
probably outweigh the undesirable effects, but the panel is 
not confident.
Basically, high-level evidence supports strong recom-
mendations, whereas biased or low-quality evidences 
generate weak recommendations. However, making rec-
ommendations for practice purposes require taking into 
account other factors, such as patients’ values and prefer-
ences, local circumstances, and clinical expertise. As a 
consequence, the strength of a recommendation can be 
downgraded (weak recommendation generated by high or 
moderate quality evidence) or upgraded (strong recommen-
dation generated from low or very low-quality evidence). 
The GRADE system formally recognizes this possibility. 
For example, poor quality of planning of a study suggesting 
high likelihood of bias, inconsistency of results, indirect-
ness of evidence, surrogate or weak end-points, lack of pre-
cision with large confidence intervals may induce the panel 
to reduce the strength of a recommendation based upon an 
RCT. Vice versa, a recommendation based upon observa-
tional studies can be upgraded in case of large magnitude 
of effect, good quality of the study, long follow-up, large 
cohorts of patients.
Postmenopausal osteoporosis (PMO)
Whom to treat
Risk factors
To prevent the fracture, any fracture risk should be evalu-
ated in the individual patient, adjusting all the modifiable 
ones [5, 6] (table I in supplemental material).
Abstract   Monitoring the effectiveness of 
treatment
Introduction    Bone turnover markers
Methodology    Bone mineral density
Postmenopausal osteoporosis  Conducting the treatment
 Whom to treat   Defining a non-responder
  Risk factors   How long to treat
  Treatment thresholds and indi-
cations to treatment
  Drug switch
 How to treat   Adherence
  Available drugs Other forms of osteoporosis
   Bisphosphonates  Male osteoporosis
    Alendronate  Androgen deprivation therapy
    Risedronate  Premenopausal osteoporosis
    Ibandronate  Aromatase inhibitors
    Zoledronate Conclusions
    Clodronate References
   Strontium ranelate
   Denosumab
   SERMs
   Hormone therapy
   Teriparatide
Introduction
The goals of treatment of osteoporosis are to prevent fra-
gility fractures and to stabilize or increase bone mineral 
density (BMD). Several drugs with different efficacy and 
safety profiles are now available, but no drug can be indefi-
nitely used once started. The long-term therapeutic strat-
egy should be planned, and the initial treatment selected 
according to the individual site-specific fracture risk when 
therapy is started and the need to give the maximal protec-
tion when the fracture risk is highest (i.e. later in life).
Regardless of the drug used, adequate calcium intake 
and vitamin D status are prerequisites of any osteoporosis 
prevention and treatment program [1].
The aim of the present consensus was mainly to review 
the available literature on the drug treatment of postmenopau-
sal osteoporosis (PMO); some particular forms of secondary 
osteoporosis were reviewed as well. Our purpose was to pro-
vide endocrinologists with an easy tool for the management 
of osteoporotic patients in their clinical practice, thus we did 
not address epidemiology, classification, pathogenesis.
Methodology
The methodology of the present Consensus is based upon 
the Grading of Recommendations, Assessment, Develop-
ment, and Evaluation (GRADE) system [2–4].
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BMD is the major risk factor especially in over 65-year 
women. A decrease in BMD of about 1 SD represents an 
increased risk factor ranging from 1.5 to 2.5, depending 
mostly on the capacity of the BMD to predict the fracture 
risk on the same site. This relationship decreases with age, 
especially for hip fracture [7].
Puberty is a crucial period characterized by bone mass 
acquisition. Any adverse event affecting puberty directly 
(e.g. delayed puberty, hypogonadism) or indirectly (e.g. 
anorexia nervosa, starvation, excess physical activity) 
might permanently compromise peak bone mass acquisi-
tion both quantitative and qualitative [7–9].
Aging makes risk fracture increase, especially at the hip. 
Over 50 years, postmenopausal women double the risk 
of fractures every 7 or 8 years, being 70 and 82 years the 
median age for vertebral fracture and hip fracture, respec-
tively [10]. In men, the risk of fractures increases later, 
becoming clinically relevant after 65–70 years [11, 12].
Genetic factors seem to be the principal determinants in 
peak bone mass. Patients whose first-degree relatives are 
osteoporotic or suffered prior fracture have a lower BMD 
and increased fracture risk [13].
A prior osteoporotic fracture induces an increased risk 
for future fractures: prior forearm fracture is associated 
with a twofold increased risk of another fracture [14] and 
the risk of future vertebral deformities over 3 years is five-
fold higher in patients with prior deformities. The risk of 
recurrent fracture is higher as the number of preexisting 
fractures increases, regardless of BMD adjusting.
Low body mass index (BMI < 18 kg/m2) is a risk factor 
for low BMD, and, in older women, thinness is associated 
with increased fracture risk [15].
Several lifestyle factors negatively affect BMD and frac-
ture risk: cigarette smoking, heavy alcohol consumption, 
absence of physical activity, low calcium and/or vitamin D 
intake, high caffeine intake [16].
The reduction of estrogens after menopause increases 
bone resorption, mostly after 3–4 years. In the first 
5–7 years after menopause bone loss is estimated to be 
about 10 % at the spine, 5 % at the femoral neck (FN), and 
7 % in the whole body. With aging, postmenopausal women 
also develop an increased fracture risk ratio. Women with 
early-onset menopause (before 40 years) are at greater risk 
of developing osteoporosis [17].
Secondary causes of fracture risk are specific medica-
tions and chronic or genetic diseases (table II in supple-
mental material) [5, 6].
Secondary osteoporosis occurs in almost two-thirds of 
men, more than half of premenopausal and perimenopau-
sal women, and about one-fifth of postmenopausal women. 
It is essential to identify and manage any cause of second-
ary osteoporosis. Failure to do so may result in further bone 
loss despite pharmacologic intervention. A few exams, 
together with the history of the patient, can exclude up to 
90 % of secondary osteoporosis (table III in supplemental 
material) [18].
Recommendations
We recommend considering patient’s age in order to
evaluate increased fracture risk
We recommend asking about previous fractures in
patient’s first-degree relatives
We recommend asking about previous fractures in the
patient (including evaluation of vertebral osteoporotic
deformities)
We suggest considering low-weight as an increased
fracture risk
We suggest inquiring patient’s past health status at the
time of puberty
We suggest inquiring patient’s lifestyle habits
potentially impacting fracture risk (e.g. cigarette
smoking, heavy alcohol consumption, absence of
physical activity, low calcium intake, low vitamin D
intake, high caffeine intake)
We recommend evaluating BMD value as predictive of
fracture risk
We recommend evaluating BMD in women with an
early-onset menopause or in women with any other
fracture risk at the menopause onset
We recommend ruling out any secondary cause of
osteoporosis including medications and chronic
diseases
We recommend checking for signs and/or symptoms of
hypogonadism in men
Treatment thresholds and indications to treatment
Even though fracture risk is higher in osteoporotic women, 
the great bulk of fractures occur in the far largest popula-
tion of osteopenic women [19]. Many osteoporotic patients 
with a prior fracture are not tested with a dual-energy 
X-ray absorptiometry (DEXA) exam, even if these high-
risk patients are most likely to benefit from osteoporosis 
treatment.
FRAX®, an algorithm approved by the WHO for esti-
mating the 10-year risk probability of hip and other major 
osteoporotic fracture [20], should be the tool to identify 
those patients candidate to pharmacological interven-
tion [21]. FRAX has been validated in different countries 
(Italy is validating DeFRA, a FRAX derived algorithm) 
but there is no universally accepted fracture risk level for 
osteoporosis pharmacological therapy. Therefore, inter-
vention thresholds vary from country to country [22, 23], 
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depending on treatment cost-effectiveness, reimbursement 
issues, and health care system [24, 25].
Guidelines from National Osteoporosis Foundation 
and American Association of Clinical Endocrinologists 
(AACE) continue to recommend treatment of patients with 
hip and vertebral fractures and those with a central DEXA 
T-score ≤−2.5, but since 2008 they also began to recom-
mend treatment of patients with DEXA-based T-scores 
between −2.5 and −1 if they had 10-year hip fracture 
probability ≥3 % or major osteoporotic-related fracture 
probability ≥20 % [26, 27].
In any clinical situation fracture risk should be assessed 
only if its evidence would influence the treatment [28].
Recommendations
We recommend assessing fracture risk in all
postmenopausal women and in men over 50
We recommend education to a correct lifestyle in all
persons with modifiable fracture risk factors
We suggest assessing 10-year fracture risk (with FRAX
or DeFRA) and performing BMD assessment in all
subjects with non-modifiable fracture risk factors
We suggest reassessing 10-year fracture risk (with
FRAX or DeFRA) in all subjects with modifiable
fracture risk factor after correcting lifestyle
We recommend considering for treatment all subjects
with a BMD assessment T-score ≤–2.5 SD
We recommend considering for treatment all subjects
with a prior fragility fracture, regardless of BMD
measurement
We recommend considering for treatment all subjects
with DEXA-based T-scores between –2.5 and –1 SD
and with an increased 10-year fracture risk evaluated
with a fracture risk algorithm (FRAX or DeFRA)
How to treat
Since all the registration trials, demonstrating the effective-
ness of therapies for osteoporosis, associated calcium and 
vitamin D to the active treatment, it is mandatory to include 
calcium and vitamin D in every pharmacological treatment 
strategy.
Available drugs
Table 1 lists the drugs commonly used in the treatment of 
osteoporosis. Etidronate and calcitonin are still on the mar-
ket, but are not included due to their scarce use.
Bisphosphonates (BPs) BPs attach to hydroxyapatite 
binding sites on bone surfaces where they are taken up by 
osteoclasts during bone resorption. Inside osteoclasts BPs 
inhibit the farnesyl-pyrophosphate synthase, and impair 
their ability to form a ruffled border, to adhere to the bone 
surface and produce protons, thus inducing osteoclasts 
apoptosis and inhibition of bone resorption [29, 30].
All oral BPs may induce gastrointestinal adverse events, 
including dyspepsia, dysphagia, and esophageal ulcers 
[31]. Among tablet formulations it is hypothesized that 
branded compounds are better tolerate than generics, likely 
due to differences in the technical production process or in 
the formulation of excipients [32].
The safety of long-term BPs therapy is unclear. Post-
marketing reports of rare but serious adverse events, likely 
associated with prolonged therapy, such as atypical femo-
ral fractures (AFF), osteonecrosis of the jaws (ONJ) and 
esophageal cancer, prompted the Food and Drug Adminis-
tration to perform a systematic review of long-term efficacy 
and safety of these drugs. Data were conflicting and the 
committee did not support a regulatory restriction on the 
duration of drug use [33, 34].
Alendronate Alendronate increases BMD and reduces 
the risk of vertebral and non-vertebral fractures at 3–4 years 
in women with PMO defined as either having existing ver-
tebral fracture or FN T-score ≤−2.5 [35, 36].
The risk reduction rate is highly significant (p < 0.001) 
for radiologic vertebral fractures (48 %), multiple radio-
logic vertebral fractures (87 %), any clinical fracture 
(30 %), and any non-vertebral clinical fracture (27 %). Risk 
of hip fracture is reduced by 53 % (p < 0.005), clinical ver-
tebral fracture by 45 % (p < 0.003), and wrist fracture by 
30 % (p < 0.038). The reduction in risk is apparent since 
the first year of treatment for clinical vertebral fractures 
Table 1  Approved drugs for osteoporosis
Class Molecule Oral Injectable
Bisphosphonates Alendronate ×
Risedronate ×
Ibandronate × ×
Zoledronate ×
Clodronate × ×
Strontium ranelate ×
Anti-RANKL antibody Denosumab ×
SERMs Raloxifene ×
Bazedoxifene ×
Lasofoxifene ×
Hormone therapy Estrogens (±progestins) ×
PTH analogs Teriparatide ×
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and for any clinical fracture, by month 18 for hip fracture, 
by month 24 for non-vertebral fracture and by month 30 for 
wrist fracture [36].
There are few available data for assessing the efficacy 
of long-term BP use. The evidence regarding continuing 
treatment beyond 5 years [37] demonstrates that from 5 to 
10-year treatment with alendronate leads to a continuous 
increase in vertebral BMD, stabilization of femoral BMD, 
and a reduction of incident clinical (symptomatic) vertebral 
fractures (RR 0.45; 95 % CI 0.24–0.85). No evidence exists 
on the overall reduction in non-vertebral fractures, due to 
the limited size of the extension trial and the small numbers 
of fractures [33, 37].
Data from the FLEX study suggest that patients with 
low FN BMD (T-score <−2.5) after 3–5 years of treat-
ment with alendronate and those with an existing vertebral 
fracture show the highest risk for future vertebral fractures, 
while patients with a FN T-score >−2.0 or without verte-
bral fracture have a lower risk degree [33, 37].
Alendronate has been licensed in Europe as oral formu-
lation (tablets of 10 mg/day and 70 mg/week) and, more 
recently, as a drinkable solution and effervescent formula-
tion [31].
Risedronate In women with PMO 3 years of 5 mg/day 
risedronate significantly reduced the risk of vertebral frac-
ture (−41 to 49 %) in two placebo-controlled RCTs [38, 
39] since the first year of therapy. It remained reduced 
through 7 years of treatment [40, 41], although studies did 
not include a placebo group after 5 years.
Two studies evaluated the effect of risedronate therapy 
on the risk of non-vertebral fracture: an RCT reported a 
39 % reduction [42], while the 33 % reduction reported in 
the other study was not statistically significant versus pla-
cebo [39].
In an RCT enrolling 5445 postmenopausal women (age 
range 70–79 years), risedronate (5 mg/day) reduced the hip 
fracture risk by 40 % in women with a densitometric diag-
nosis of osteoporosis, and by 60 % in the subgroup with 
prior vertebral fractures, though the latter result derives 
from a post hoc analysis [43].
A 2-year RCT on early postmenopausal non-osteo-
porotic women (mean age, 51–52 years) showed that rise-
dronate (5 mg/day) led to a significant BMD increase at 
lumbar spine (LS, +5.7 %) and femur (+5.4 %) [42].
In older postmenopausal women, lumbar and femoral 
BMD increased significantly (+4.3 and +2.8 %, respec-
tively) after 3 years of risedronate therapy (5 mg/day) as 
compared with placebo-treated matched controls [38].
Risedronate therapy for 7 years increased BMD by 
11.5 % from baseline [41].
Risedronate has been approved in Europe for the treat-
ment of PMO in oral tablets (5 mg/day, 35 mg/weekly and 
75 mg on 2 consecutive days once a month).
Ibandronate In a 3-year placebo-controlled study on 
postmenopausal women (mean age 69 years) with low spi-
nal BMD and vertebral fractures, oral ibandronate (2.5 mg/
day) reduced significantly the risk of morphometric verte-
bral fracture by 52 % but did not reduce the non-vertebral 
fracture risk in the overall study population. A post hoc 
analysis showed that the treatment might reduce (−69 %) 
the risk of non-vertebral fracture in the subgroup of patients 
with baseline FN T-scores <−3 [44].
Ibandronate significantly increased spinal and femoral 
BMD (+5.2 and +4.1 %, respectively) in postmenopausal 
women with low spinal BMD [44].
In early postmenopausal women (mean age 57.6–
58.8 years) without osteoporosis a two-year treatment with 
oral ibandronate (2.5 mg/day) led to a small, though signifi-
cant, LS and hip BMD increase (+1.9 and +1.2 %, respec-
tively) [45].
No data are available on the effects of long-term iban-
dronate therapy.
Ibandronate is approved for the treatment of PMO both 
as a 150-mg tablet once a month and as a 3-mg intra-venous 
(IV) formulation every 3 months (not reimbursed in Italy).
Zoledronate Zoledronate is the most powerful BP: 60 % 
is taken up by the skeleton after a 15-min IV infusion [46]. 
Once-yearly IV infusion of zoledronate (5 mg), during a 
3-year period, significantly reduced the risk of vertebral, 
hip and non-vertebral fractures in women with PMO; more-
over zoledronate increased BMD at all skeletal sites [47].
The infusion within 90 days after surgical repair of an 
osteoporotic hip fracture is associated with a reduction 
of new clinical fractures and improved global survival at 
36 months [48].
Many patients can discontinue zoledronate after 3 years, 
but those at high risk of fracture may benefit by continuing 
treatment up to 6 years [49].
Flu-like symptoms may occur, particularly during the 
first administration. Paracetamol or ibuprofen alleviates 
post-dose symptoms that are commonly transient (lasting 
1–3 days). In case of severity and persistence steroids may 
be helpful [50]. Gastrointestinal problems, local reaction 
at the injection site and uveitis are minor complications of 
zoledronate treatment.
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Concerns on cardiac action [47] were ruled out by clini-
cal data that did not disclose significant difference in inci-
dence of atrial fibrillation [51].
IV zoledronate is not recommended in subjects with 
severe renal impairment (creatinine clearance <30 mL/
min), but clinical trial showed that IV BPs did not result in 
long-term renal function decline [52].
ONJ is related to both the potency and duration of BP 
therapy. Occurrence of ONJ is rare in patients with osteo-
porosis who are receiving once-yearly zoledronate. Data 
from five clinical trials indicated that ONJ incidence is <1 
in 14,200 treated patient per year [53].
The risk of AFF may rise with increasing duration of 
exposure to BPs (alendronate or risedronate) while in zole-
dronate-treated patients the risk is unknown [54].
Zoledronate 5 mg IV yearly is approved for the treat-
ment of PMO.
Clodronate A double-blind placebo-controlled trial 
proved the efficacy of 800 mg daily oral clodronate both 
in increasing BMD and in reducing the incidence of single 
and multiple vertebral fractures in a group of women with 
PMO or secondary osteoporosis, with or without prior ver-
tebral fractures [55]. Oral clodronate is also effective and 
comparable to other BPs in reducing all clinical fractures 
in elderly women, while it seems to be less effective on hip 
fractures [56].
A recent meta-analysis underlined the efficacy of clo-
dronate in reducing the risk of new vertebral, non-vertebral 
and overall fractures but the majority of the data are from 
studies with oral clodronate [57].
Oral clodronate given at a dose of 1600 mg/day, for at 
least 3 years, in women with normal BMD or with osteo-
penia affected by early stage breast cancer (BC) and treated 
with adjuvant chemotherapy or anti-estrogen treatment, 
increased BMD, with effects lasting for 7 years after treat-
ment discontinuation [58].
Weekly 100 mg intramuscular clodronate is registered in 
Italy for PMO treatment but it is not reimbursed. There are 
few low-quality studies concerning the effects of this for-
mulation on fractures [59, 60].
Clodronate (generally at an oral daily dose of 1600 mg) 
is approved in patients with BC and it has been used also 
in subjects with myeloma and less frequently in other solid 
tumors with or without bone metastases [61].
Clodronate cannot be a real therapeutic option in Italy 
because oral formulation has no indication for PMO and at 
present it is not reimbursed by the Italian National Institute 
of Health.
Recommendations
We recommend the use of alendronate, risedronate,
ibandronate or zoledronate to reduce the risk of
vertebral fractures in women with PMO
We recommend the use of alendronate, ibandronate or
zoledronate and suggest the use of risedronate to
reduce the risk of non-vertebral fractures in women
with PMO
We recommend the use of risedronate or zoledronate and
suggest the use of alendronate to reduce the risk of hip
fractures in women with PMO
We recommend the use of alendronate, risedronate,
ibandronate, or zoledronate to increase BMD in
women with PMO
We suggest the use of oral clodronate in women with
low BMD at risk for fractures
We suggest reevaluation and discontinuation of therapy
in women who become low-risk (BMD T-score– 2
and/or absence of fractures at the time of reassessment)
after a 3 to 5-year alendronate, or after a 5-year
risedronate, or after a 3-year zoledronate treatment
In women who remain at high risk (T-score ≤–2.5 and
the presence of fracture at the time of reassessment)
after a 3 to 5-year BP treatment, we suggest the
extension of therapy with alendronate up to 10 years,
or with risedronate up to 7 years
We recommend the extension of therapy with
zoledronate up to 6 years in women who remain at
high risk after a 3-year treatment (T-score ≤–2.5 and
the presence of fracture at the time of reassessment)
We suggest the use of weekly intramuscular 100 mg
clodronate in women with PMO when all other
treatments cannot be used
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Strontium ranelate (SrR) The mechanism of action of 
SrR is still not completely known, even though it seems to 
increase bone formation and reduce bone resorption [62–64].
SrR increases BMD and reduces the risk of vertebral 
and non-vertebral fractures at 3 and 5 years in women with 
PMO [62, 63]. It reduces the relative risk of hip fractures in 
subjects older than 74 years and T-score <−3 [62]. Open-
label extension of these trials (up to 10 years) showed fur-
ther increase in BMD [64].
SrR has been approved in Europe, as an oral 2-g daily 
formulation, for the prevention of vertebral and non-verte-
bral osteoporotic fractures in osteoporotic women.
SrR has been associated with an increased risk of venous 
thromboembolism and with rare cases of severe allergic 
skin reactions [65]. More recently, long-term post-approval 
surveillance safety analyses showed an increased cardio-
vascular risk in patients treated with SrR [66], though not 
confirmed by other analysis [67, 68]. SrR is now contrain-
dicated in patients with a history of cardiovascular and cer-
ebrovascular disease, and uncontrolled hypertension [69]. 
Patients should be evaluated for cardiovascular risk before 
starting treatment with SrR and at regular intervals during 
treatment [65, 69].
Recommendations
We suggest the use of SrR both in postmenopausal
women and in men with severe osteoporosis and
concomitant contraindications or intolerance to all the
other available drugs
We recommend against the use of SrR in patients with
previous or current venous thromboembolism or in
those with temporary or permanent immobilization as
well as in those subjects with uncontrolled
hypertension, ischemic heart disease, obliterating
arteriopathy of the lower limbs or cerebrovascular
diseases
Denosumab RANK ligand (RANKL) induces osteoclas-
togenesis by binding to its receptor (RANK). The inter-
action between RANKL and RANK can be blocked by a 
decoy receptor called osteoprotegerin, as well as by deno-
sumab, a fully human antibody against RANKL. The effect 
of denosumab is the reduction of formation, function and 
survival of osteoclasts, which determines both a reduction 
of bone resorption and an increase of BMD. The drug is 
administered SC every 6 months. It is not cleared by kid-
neys, thus it can be used in patients with renal failure [70].
In PMO 36-month denosumab treatment reduced the 
incidence of vertebral, hip and non-vertebral fractures 
(−68, −40, and −20 %, respectively) [71]. Denosumab 
reduced the risk of vertebral, non-vertebral and hip frac-
tures in patients older than 75 years [72, 73].
In the 5-year extension study denosumab induced gains 
in BMD at LS and total hip (TH) (+13.7 and +7 %, respec-
tively) [74]. In naïve-to-treatment PMO BMD increased 
more with denosumab than with alendronate [75], and in 
patients previously treated with BP the switch to deno-
sumab induced a greater increase in BMD [76].
Denosumab is safe and well tolerated. Dermatological 
adverse events (i.e. dermatitis, rash, eczema, and in particu-
lar cellulitis and erysipelas) were more prevalent in treated 
patients than in placebo, although the number of events was 
very low (0.3 %). Hypocalcemia has been reported but not 
in patients assuming calcium and vitamin D. Few cases of 
ONJ and two of AFF have been reported, while there is no 
apparent increase of cancer or cardiovascular diseases.
Recommendations
We recommend the use of denosumab to reduce the risk
of vertebral, non-vertebral and hip fractures in PMO
We recommend the use of denosumab to increase BMD
in PMO
We suggest the use of denosumab to increase BMD in
osteoporotic men
Selective estrogen receptor modulators (SERMs) SERMs 
are non-steroidal compounds that bind to the estrogen 
receptor, acting as agonist or antagonist, depending on the 
target tissue.
Treatment with SERMs is associated with an increased 
frequency of hot flushes, leg cramps and venous thrombo-
embolic events [77–80]. No adverse endometrial effect is 
observed with raloxifene and bazedoxifene [81], whereas 
an increased, but not clinically significant, endometrial 
thickness is associated to lasofoxifene [82].
Raloxifene (60 mg daily) is approved in the USA and 
Europe for the prevention and treatment of PMO. In a 
3-year, placebo-controlled RCT in postmenopausal women 
with osteoporosis (T-score <−2.5) or low bone mass and 
prior vertebral fracture, raloxifene decreased the risk of 
new vertebral fractures by 50 and 30 %, respectively [77]. 
Raloxifene had no effect on the rate of non-vertebral and 
hip fracture [77]. Raloxifene showed effectiveness also in 
increasing BMD and reducing the risk of vertebral frac-
tures in postmenopausal women with osteopenia [83].
Bazedoxifene (20 mg daily) is approved in Europe for 
the treatment of PMO in women at increased risk of frac-
ture. In a 3-year placebo-controlled RCT in PMO, with or 
without prior vertebral fractures, bazedoxifene decreased 
the risk of new vertebral fractures by 42 % [84]. In a 2-year 
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extension of the study, bazedoxifene decreased the risk of 
new vertebral fractures by 35 % [85]. Bazedoxifene had no 
effect on the rate of non-vertebral fracture and hip fracture. 
In a 2-year placebo-controlled RCT bazedoxifene associ-
ated with conjugated estrogen significantly increased BDM 
at the LS and hip [86].
Lasofoxifene (0.5 mg daily) is approved in Europe for 
the treatment of PMO in women at increased risk of frac-
ture. In a 5-year placebo-controlled RCT in PMO, lasofox-
ifene decreased the risk of new vertebral fractures and non-
vertebral fractures by 42 and 24 %, respectively, but not hip 
fractures [77].
Recommendations
We recommend the use of raloxifene, bazedoxifene or
lasofoxifene to reduce the risk of vertebral fractures in
women with PMO
We suggest the use of lasofoxifene to reduce the risk of
non-vertebral fractures in women with PMO
We suggest the use of raloxifene, bazedoxifene or
lasofoxifene to increase BMD in women with PMO
Hormone therapy (HT) Estrogens reduce the accelerated 
bone turnover induced by menopause and prevent bone loss 
at all skeletal sites regardless of age and duration of ther-
apy. The beneficial effects of systemic oral or transdermal 
estrogen therapy (ET) or estrogen plus progestin (EPT) for 
women with or without a uterus, respectively, on BMD pres-
ervation are established. RCTs indicated that standard doses 
of ET/EPT reduce spine and non-vertebral (including hip) 
fractures [87–89]. In the Million Women Study, when the 
overall fracture risk reduction was examined by type of hor-
mone, no difference was found between ET and EPT [90]. 
Results were not influenced by sequential or continuous pro-
gestin use [90]. The RR of fracture was not different when 
specific estrogen or progestin products were compared (i.e. 
conjugated estrogens vs. estradiol; medroxyprogesterone 
acetate (MPA) vs. norethisterone or norgestrel/levonorg-
estrel) [90].
The benefits of HT on bone mass and fracture reduc-
tion dissipate quickly after discontinuation [91, 92], requir-
ing the transition to a different treatment to preserve bone 
mass. In the Women’s Health Initiative (WHI), women in 
the EPT/ET group who stopped HT for a few years had a 
rate of fractures equivalent to that of women assigned to 
placebo [91, 92]. The long-term risks of HT outweighed 
the benefits because systemic estrogen and MPA at stand-
ard doses for 5.6 years significantly increased risk of BC, 
stroke, coronary heart disease (CHD) and thromboem-
bolic events [93–95]. In women who had undergone a 
hysterectomy, ET alone for 6.8 years resulted in a statisti-
cally significant increased risk of stroke and deep venous 
thrombosis, whereas BC, CHD, and pulmonary embolism 
were unchanged, suggesting a deleterious effect of MPA 
[96].
Recommendations
We recommend against the use of HT to reduce the risk
of fractures in PMO
We suggest a possible use of HT, rather than other bone-
specific treatments, in women experiencing an early
menopause who require prevention of bone loss until
they reach the normal age of menopause at which time
treatment should be reassessed
Teriparatide The 1–34 N-terminal fragment of PTH (teri-
paratide, 20 μg daily by SC injection) is the only approved 
anabolic therapy for the management of PMO at increased 
risk of fracture [97]. The duration of treatment is limited to 
a maximum of 2 years.
Teriparatide is well tolerated, but nausea, pain in limbs, 
headache and dizziness were reported [98]. Contraindica-
tions to treatment include severe renal impairment (GFR 
<30 mL/min), primary hyperparathyroidism, Paget’s dis-
ease, unexplained elevation of alkaline phosphates, prior 
radiation therapy, skeletal malignancy, and bone metas-
tases. The increased risk of osteosarcoma in rats was not 
confirmed for the relatively short-term use in humans [99].
In an RCT in women with prevalent vertebral fractures, 
teriparatide, compared with placebo, decreased the risk of 
new vertebral and non-vertebral fractures by 65 and 35 %, 
respectively, after a median 19-month treatment [100]. The 
beneficial effect on fracture risk persisted after discontinu-
ation of therapy for 18 months for vertebral fractures and 
30 months for non-vertebral fractures (both 40 % reduction 
vs. placebo) [101, 102].
BP administration upon termination of teriparatide may 
strengthen the beneficial effect of therapy [101–103]. The 
efficacy of teriparatide may be variably attenuated by prior 
treatment with anti-resorptive drugs according to their 
potency [104–109].
Recommendations
We recommend the use of teriparatide to reduce the risk
of vertebral and non-vertebral fractures in PMO and
osteoporotic men
We suggest the use of teriparatide to increase BMD in
PMO
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Table 2 summarizes the efficacy of different drugs on 
fracture risk in PMO.
Monitoring the effectiveness of treatment
Bone turnover markers (BTMs) BTMs may show a large 
and rapid response to the pharmacological treatment of oste-
oporosis. BTMs may offer an attractive monitoring strategy 
as they are non-invasive, relatively cheap, and able to detect 
changes in bone metabolism earlier than and independent 
from BMD variations [110]. As all studies have limitations 
due to significant pre-analytical and analytical variability of 
BMTs, the International Osteoporosis Foundation and the 
International Federation of Clinical Chemistry and Labo-
ratory Medicine recommended the standardization of one 
marker of bone formation (if possible N-terminal propeptide 
of procollagen type 1, P1NP) and one of bone resorption (if 
possible serum collagen type I C-telopeptide, CTX) [110].
Almost all the published studies focused on the effec-
tiveness of BTMs in predicting BMD changes during oste-
oporosis therapy [111], but the strength of this association 
was poor [112, 113].
Scanty data correlated fracture risk reduction with vari-
ation of BTMs; weak evidence supports their role in moni-
toring anti-resorptive therapy [62, 114–117], as well as in 
measuring fracture risk reduction during treatment with 
teriparatide or SrR [62, 117]. Nevertheless bone resorption 
markers seem to be more accurate than formation ones in 
predicting both bone loss rate and fracture risk reduction 
[118].
Evidence is still lacking about the threshold at which 
BTMs should be considered over-suppressed and poten-
tially related with complications such as AFF.
Recommendation
We recommend against routine use of BMTs in
evaluating the effects of anti-osteoporosis drugs
Bone mineral density BMD testing of central skeletal sites 
(spine and hip) by DEXA is considered the international 
standard for detecting osteoporosis, determining the risk of 
fracture, identifying the candidates to treatment and moni-
toring the efficacy of drugs. The goal of drug therapy for 
osteoporosis is to significantly increase bone strength, with 
BMD being one of the major determinants of this parameter 
[119], as well as to reduce fractures.
Changes in BMD reportedly account only for a small 
part of the fracture risk reduction seen in patients treated 
with anti-resorptive drugs [120]. In the FIT Study, spine 
BMD increase could explain only 16 % of the risk reduc-
tion of vertebral fracture [112]. In patients treated with rise-
dronate or raloxifene the changes in BMD correlated even 
more poorly with the degree of vertebral or non-vertebral 
fracture risk reduction. As a matter of fact patients taking 
risedronate, regardless whether their LS or hip BMD was 
increased or not, showed a similar incidence of non-ver-
tebral fractures [121]. Similarly, raloxifene-induced BMD 
increase was able to explain only 4 % of the observed verte-
bral fracture risk reduction, with the remaining 96 % being 
unexplained [122]. A higher correlation was described for 
teriparatide, whose action on BMD could explain from 30 
to 41 % of vertebral fracture risk reduction [123].
More clear data were published on denosumab and SrR, 
suggesting that a larger proportion of their anti-fracture 
efficacy might be explained by changes in TH or FN BMD. 
A risk reduction up to 35 % for new or worsening vertebral 
fractures and up to 87 % for non-vertebral fractures can be 
explained by denosumab-induced increase of BMD [124]. 
SrR changes in hip and FN BMD have been correlated with 
a vertebral fracture risk reduction by 74 and 76 %, respec-
tively [125].
BMD monitoring may help in identifying non-responder 
or non-compliant subjects; DEXA should be measured 
1–2 years after starting or changing any anti-osteoporo-
sis therapy [126]. These intervals are based both on the 
observed rates of change induced by anti-resorptive agents 
and on the reproducibility of DEXA testing. Once effi-
cacy has been established, less frequent intervals between 
DEXA scans seem appropriate.
Table 2  Efficacy of different treatments on fracture risk in postmen-
opausal women (from 36, 38, 39, 42, 43, 44, 47, 48, 55, 62, 63, 71, 
72, 73, 77, 79, 84, 100)
Beware that results are not to be regarded as comparative between 
different drugs, since they are not derived from head to head studies
− no available data or negative data, ± fracture risk decrease reported 
only in post hoc analyses, + fracture risk decreased vs. placebo
Drug Vertebral Non-vertebral Hip
Alendronate + + +
Risedronate + + +
Ibandronate + ± –
Zoledronate + + +
Clodronate (800 mg/day, orally) + + –
Strontium ranelate + + ±
Denosumab + + +
Raloxifene + – –
Bazedoxifene + ± –
Lasofoxifene + + –
Teriparatide + + –
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Whether greater treatment-related changes in BMD 
result in greater decreases in fracture risk is controversial 
[127], but BMD testing alone seems to predictably under-
estimate the extent of fracture risk reduction induced by 
therapy. Other determinants of bone strength but BMD, like 
bone geometry, microarchitecture, remodeling rate, damage 
accumulation and collagen/mineral matrix properties, play 
an important role in reducing fracture risk.
Recommendations
We suggest monitoring BMD changes induced by anti-
osteoporosis therapy, even though they may
underestimate the extent of fracture risk reduction
We recommend testing BMD at intervals not routinely
shorter than 18–24 months and if possible in the same
center with the same equipment to minimize variability
Conducting the treatment
Defining a non‑responder
A number of targets were proposed in osteoporosis treat-
ment and this makes possible to assess a treatment failure 
[128, 129]. BTMs and changes in BMD are the main can-
didates for these targets. Another controversial point is that, 
since drug therapy does not eliminate fracture risk, sustain-
ing a single fracture during treatment should not be consid-
ered failure, as the risk of a new fracture decreases signifi-
cantly during the treatment [130, 131].
Regarding BTMs, in a post hoc analysis of the FIT 
study, osteoporotic women with higher baseline levels 
of P1NP, CTX and bone-specific alkaline phosphatase 
(BSAP) showed a greater reduction in risk of non-verte-
bral (but not vertebral) fractures in response to alendronate 
than those with low levels [132]. Major reductions in one 
or more BTMs were reportedly associated with substan-
tial reductions in vertebral, non-vertebral and hip fractures 
in women treated with alendronate [114]: the greater the 
reduction in BTMs, the lower is the risk of fracture. FIT 
study showed that women in the alendronate group, with 
a reduction of at least 30 % of BSAP, had a lower risk of 
non-vertebral and hip fractures. This effect was just as 
strong as the anti-fracture effect observed with changes in 
BMD after 1 year [114]. A <25 % fall in serum CTX (the 
least significant change, LSC, at 95 % confidence) on an 
anti-resorptive drug or teriparatide should be considered a 
treatment failure [110].
Much more controversy exists in relation to target BMD 
values during osteoporosis treatment. Some studies sug-
gested that even patients with a decline in BMD might still 
benefit from oral BP therapy [133]. In clinical trials of alen-
dronate, risedronate, and ibandronate, 8–25 % of patients 
had BMD change ≤0 % at the LS after 2 years of treat-
ment. Post hoc analyses suggested that patients who expe-
rienced an increase in BMD had a lower vertebral fracture 
risk than those with a decline in BMD (range 38–50 %). 
Additional analyses suggested that patients who experi-
enced a decline in BMD while receiving oral BP therapy 
still appeared to receive some benefit (fracture risk reduc-
tion, 38–60 %) from the treatment compared with those 
on a placebo [133]. It may, therefore, be difficult to tell a 
patient on BP treatment with a declining BMD over time 
that he/she has really lost his/her protection against osteo-
porotic fractures. Thus, a decline in BMD ≥5 % at the LS 
and ≥4 % at the FN (corresponding to LSC at 95 % con-
fidence) or a new fragility fracture should be considered 
treatment failure, as well as a reduction in serum CTX on 
anti-resorptive drugs or an increase on teriparatide smaller 
than LSC for the used marker.
Recommendations
We recommend considering treatment failure a second
fragility fracture occurring on treatment
We recommend considering treatment failure a decline
in BMD ≥5 % at the LS and ≥4 % at the FN
We recommend considering treatment failure a change
in serum CTX–25 % on anti-resorptive therapy or
+25 % on teriparatide
How long to treat
BPs continue to be the first-line agents to treat osteoporo-
sis due to their efficacy, low cost, possible extra-skeletal 
effects [134], and the possibility of a residual effect follow-
ing cessation of therapy [37, 49]. On the other hand, BP-
associated AFF, although rare, may cause a considerable 
impact on the patient’s quality of life and should also be 
considered in planning when to stop or change therapy [54, 
135–137]. This is mainly due to the fact that after 5 years of 
BP treatment, there is a sharp increase from 0.13 to 0.22 % 
in the risk of AFF [136].
There are extension studies on alendronate, zoledronate 
and risedronate showing that patients may experience a 
residual effect after stopping therapy (“drug holiday”) 
[37, 41, 49]. The benefit of continuing alendronate beyond 
5 years has been observed for clinical vertebral fracture 
only [37]. Taken together, the rates of osteoporotic frac-
tures were similar in patients who continued or stopped 
alendronate after a 5-year treatment [138]. On the other 
hand, a post hoc analysis demonstrated that patients with 
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both no prevalent vertebral fracture at the start of FLEX 
trial and a BMD T-score ≤−2.5 would derive much more 
benefit in continuing therapy as regards clinical vertebral 
fracture risk reduction (number needed to treat in 5 years: 
24) [33]. Likewise, women with a prevalent vertebral frac-
ture at the start of FLEX trial and a BMD T-score ≤−2.0 
derived a greater benefit when remaining on alendronate 
[33]. Women who were on 5 mg/day during FLEX study 
had a similar benefit to those on a 10-mg dose, suggesting 
that alendronate doses of less than 70 mg per week might 
be considered for treatment beyond 5 years [33].
The anti-fracture efficacy of risedronate was maintained 
for up to 7 years of treatment, and women who switched 
from placebo to risedronate at 5 years significantly 
decreased the incidence of vertebral fractures during the 
sixth and seventh years [41]. An extension study with zole-
dronate beyond 3 years showed that women who continued 
annual infusions for up to 6 years had a 49 % reduction 
in the risk of morphometric vertebral fractures compared 
with those who stopped at 3 years [49]. Women with a FN 
T-score at 3 years ≤−2.5 benefited much more from con-
tinuing treatment for 6 years [49].
Recommendations
We recommend continuing therapy in patients with no
prevalent vertebral fracture, after 5 years on oral
alendronate or risedronate and a T-score BMD≤–2.5
We recommend continuing therapy in patients with a
prevalent vertebral fracture, after 5 years on oral
alendronate or risedronate and a T-score BMD ≤–2.0
We suggest considering the possible use of oral
alendronate doses lower than 70 mg per week for
treatment beyond 5 years
We recommend continuing annual infusions of
zoledronate for up to 6 years in patients with a
prevalent vertebral fracture, or in patients without
prevalent fractures but with a FN T-score at 3 years
≤–2.5
Drug switch
In the high-risk patient one alternative is to change therapy 
to a class of osteoporosis medication with no pure anti-
resorptive effect or an osteoanabolic one, that is, SrR or 
teriparatide, respectively [139–142].
Postmenopausal women switched to SrR after long-
term BP use showed different responses in BTMs in com-
parison to women who never used them [139–141]. There 
were short-term increases in serum CTX and osteocalcin 
[139] associated with long-term increases in BMD [140]. 
During the first 6 months of SrR therapy, there was a blunt-
ing of BMD response in patients previously treated with 
BPs compared to those who were not previously exposed 
to BPs. However, in the long term, they found a catch-up 
of BMD in those patients, along with an increase in BTMs 
(CTX, P1NP, and BSAP) [141].
The anti-fracture efficacy of teriparatide was compared 
in patients previously exposed to long-term BPs with those 
who had never used BPs. They were treated with teripara-
tide for 18 months and followed up for 36 months. All frac-
tures decreased in both groups and this was maintained in 
the observation period, in which 70 % of patients were on 
BPs. Back pain and quality of life improved in both groups, 
but these improvements were more pronounced in those 
patients with no prior BP use [142].
Since teriparatide administration is limited to 2 years 
and BMD starts to decrease shortly after its discontinuation, 
sequential therapy with anti-resorptive agents after teripara-
tide treatment is highly recommended although the benefit 
in terms of fracture risk reduction is speculative [27]. Alen-
dronate [143] and, even more, zoledronate [144] and deno-
sumab [145] after teriparatide are associated with a further 
increase in BMD. Also raloxifene maintains spine BMD and 
increases hip BMD after teriparatide discontinuation [146].
Not all the patients treated with BPs can be switched 
to teriparatide due to the high cost of this therapy. A dou-
ble-blind, double-dummy RCT investigated the effects 
of switching to denosumab 504 postmenopausal women 
who had been receiving alendronate therapy for at least 
6 months. Transition to denosumab produced greater 
increases in BMD at all measured skeletal sites and a 
greater reduction in bone turnover than did continued alen-
dronate therapy [76].
Recommendations
We recommend switching to teriparatide therapy the
high-risk patients who are non-responders to BPs
We suggest switching to SrR or denosumab those
patients that cannot carry on BPs treatment due to
adverse effect of these drugs
Adherence
In a cross-sectional, observational study in 2314 women 
with PMO, the rates of noncompliance to drug treatment 
were: alendronate 14.9 %, risedronate 11.4 %, raloxifene 
11.3 %, HT 24.1 %, and tibolone 16.7 % [147]. The rates 
of gastrointestinal side effects leading to noncompliance 
were similar for alendronate and risedronate (62.7 vs. 
62.2 %) [147].
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Retrospective data showed that compliance with osteo-
porosis guidelines by physicians is not adequate [148]: 
among women diagnosed with PMO, only 13.2 % had 
appropriate BMD follow-up, 42 % were not on approved 
and guideline-endorsed pharmacotherapy for osteoporosis, 
and 26 % had a fracture after diagnosis.
As adherence seems to be a problem in osteoporosis treat-
ment both by the patient and the physician, the great vari-
ability in methods of studies that evaluate the impact of com-
pliance to drug therapy on fracture risk makes it somewhat 
difficult to draw any definite conclusions on this issue [149].
Recommendation
We suggest considering low adherence as one of the
possible causes of treatment failure, even though no
definite conclusions on this issue can be drawn due to
the lack of studies evaluating the impact of compliance
to drug therapy on fracture risk
Other forms of osteoporosis
The present document focuses on forms representing a 
challenge for the endocrinologist. Glucocorticoid-induced 
osteoporosis (GIO) has not been addressed because many 
recent documents appeared on the topic.
Male osteoporosis
The incidence of vertebral and hip fractures is lower in men 
than in women. Anyway, it has been estimated that after 
50 years one out of four men will suffer a fragility frac-
ture [150]. Morbidity and mortality after hip fractures are 
higher in men than in women, particularly after the age of 
70 [151].
Since male osteoporosis has a secondary etiology in 
many cases, before starting a drug treatment it is mandatory 
to differentiate the various forms of osteoporosis by means 
of an accurate clinical evaluation of the patient (table II in 
supplemental material) [11].
Currently the indications for drug therapy are not une-
quivocal. The use of algorithms that integrate risk factors 
with BMD may be useful in assessing fracture risk [20]. 
Pharmacological treatment must be carefully considered in 
men with a prior history of hip or vertebral fractures, par-
ticularly if they occurred after minor traumas or after the 
age of 50, or in those on long-term glucocorticoid therapy 
or having a FN BMD T-score ≤−2.5 [152].
At present many pharmacological treatments can be 
considered for osteoporosis in men: T, BPs (alendronate, 
risedronate, zoledronate), denosumab, and teriparatide.
Testosterone
T is the first-line treatment in men affected by primary or 
secondary hypogonadism [153]. Although the prevalence 
of hypogonadism in osteoporotic men has not been prop-
erly assessed, it is reasonable to measure serum T if con-
comitant symptoms or signs of androgen deficiency are 
present or suspected, subsequently considering for andro-
gen treatment only patients with T levels <200–300 ng/dL 
[154].
In men over 65 years T therapy was able to increase 
spine BMD by 3.4 % when a threshold of 300 ng/dL was 
considered, while this rate grew up to 5.9 % when plasma T 
threshold was set at 200 ng/dL [155]. No data are available 
on anti-fracture efficacy of T [156].
Bisphosphonates
A good quality trial has proven the efficacy of a 2-year 
daily oral alendronate therapy in increasing BMD. 
Although the study was not powered to assess anti-fracture 
efficacy, a not significant trend to reduction in the number 
of vertebral and non-vertebral fractures was observed in the 
treated group [157].
Similar data on BMD have been obtained with weekly 
oral risedronate, but even with this drug fracture incidence 
was not significantly different between risedronate and pla-
cebo-treated patients [158, 159].
In a 2-year multicenter, double blind RCT, once-yearly 
zoledronate (5 mg IV) increased BMD and decreased 
BTMs, comparably to 70 mg weekly oral alendronate, with 
similar incidence of adverse events [160, 161].
More recently in a multicenter, double-blind, placebo-
controlled RCT zoledronate treatment was associated with 
a significantly reduced risk of vertebral fracture among 
men with primary or hypogonadism-associated osteoporo-
sis. The treated group showed also higher BMD and lower 
BTMs [162].
The effects of BPs on BMD seem similar in men with 
normal serum T and in those with hypogonadism, but a 
recent paper on HIV-infected men, with osteoporosis or 
osteopenia, showed that risedronate increased BMD and 
reduced BTMs to a greater extent in patients with adequate 
androgenization compared to patients with symptomatic 
hypogonadism [163].
Denosumab
Denosumab is effective in reducing fracture incidence in 
men receiving ADT for non-metastatic prostate cancer (see 
below). Denosumab 60 mg SC every 6 months resulted in 
BMD increase significantly higher than placebo (+5.7 % 
at the LS, +2.4 % at the TH, and +2.1 % at the FN) in a 
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randomized, 1-year study in osteopenic men with or with-
out fractures [164].
A 24-month extension of this study, the ADAMO trial, 
evaluated the efficacy and safety of denosumab for the 
treatment of men with low BMD. After the first year men 
from the original denosumab group continued to receive 
the drug for an additional year, while those coming from 
the placebo arm were assigned to the treatment with den-
osumab. This treatment for a second year maintains the 
ability to increase BMD, together with reductions in bone 
resorption. In men initiating denosumab during the sec-
ond year BMD increased as well. The effects on BMD and 
BTMs were similar to those reported in women with PMO 
and in men with prostate cancer receiving ADT [165].
Teriparatide
Teriparatide is indicated to increase bone mass in men with 
primary or hypogonadal osteoporosis at high risk for frac-
ture. A placebo-controlled, double-blind RCT with teri-
paratide was conducted on 437 men with low BMD and a 
40 % prevalence of fractures. Almost 50 % of the enrolled 
patients had low serum T. BMD increase was significantly 
higher at all skeletal sites in the teriparatide arm of the 
study. Changes in BMD were similar to those described in 
women with PMO. Bone turnover increased significantly, 
with formation markers rising earlier than resorption ones. 
Treatment effects were independent on the presence of 
baseline low serum T [166].
Recommendations
We recommend, before starting a drug treatment, to
record a complete medical history and perform an
accurate clinical evaluation of the patient to
differentiate primary from secondary osteoporosis
We suggest T treatment in men with concomitant
symptoms of hypogonadism and T levels300 ng/dL.
Treatment may be also considered in men without
symptoms, but with T levels200 ng/dL
We suggest starting BPs, if T therapy does not increase
BMD
We recommend the use of alendronate, risedronate or
denosumab in men with osteoporosis
We recommend the use of yearly IV zoledronate or daily
SC teriparatide in osteoporotic men at high risk of
fractures
Table 3 summarizes the efficacy of different drugs on 
fracture risk in males.
Androgen deprivation therapy
ADT in men induces a severe sex-steroid deficiency result-
ing both in decreased BMD (at the hip and spine levels) 
and increased fracture incidence [167–173]. Radius BMD 
decline is faster than that at the spine and hip [174].
Men receiving ADT should receive drug therapy if they 
have a high risk of fracture as follows [151]:
•	 Low trauma hip or vertebral fractures;
•	 BMD T-score of the spine, FN and/or TH ≤−2.5 SD;
•	 Long-term glucocorticoid therapy at pharmacological 
doses.
Other studies are needed to establish the correct thera-
peutic approach for men receiving ADT who have a T-score 
between −1.0 and −2.5 at the spine, FN, or TH level, using 
national fracture risk assessment algorithms.
Physical exercise, calcium, vitamin D, BPs, denosumab, 
and SERMs have been proposed as treatment options for 
men on ADT.
Physical exercise
There are no conclusive data about the real effect of physi-
cal exercise on BMD and risk of fracture in men on ADT. A 
recent systematic review demonstrated that physical exer-
cise may ameliorate many of the treatment-induced adverse 
effects of ADT, but its impact on bone health is still unclear 
[175]. Another cross-sectional study revealed a weak posi-
tive and significant association between endurance exer-
cise and T-score of the hip. No significant correlation was 
found between physical exercise and LS T-score, even after 
adjusting for age, BMI and alcohol use [176].
Table 3  Efficacy of different treatments on BMD and fracture risk in 
males (from 156, 157, 158, 159, 160, 162, 165, 167)
Beware that results are not to be regarded as comparative between 
different drugs, since they are not derived from head to head studies
− no available data or negative data, ± fracture risk decrease 
obtained as secondary endpoint, + fracture risk decreased vs. placebo
Drug BMD increase Fractures
Vertebral Non-vertebral Hip
Testosterone Yes – – –
Alendronate Yes ± – –
Risedronate Yes ± – –
Zoledronate Yes + – –
Denosumab Yes ± – –
Teriparatide Yes ± – –
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Calcium/vitamin D
In men receiving ADT, calcium and vitamin D supplemen-
tation is controversial with inconsistent dosage recom-
mendations. A critical review, analyzing the results of 12 
clinical trials of calcium and vitamin D supplementation 
on BMD in men on ADT, showed the ineffectiveness of the 
commonly recommended doses, namely 0.5–1 g daily cal-
cium plus 200–500 IU daily vitamin D [177]. In a prospec-
tive longitudinal study, vitamin D, but not calcium, seemed 
to increase LS BMD during the first year of ADT [178]. 
On the other hand, reduced daily calcium intake potentially 
represents an independent risk factor for osteoporosis in 
these patients [179].
Bisphosphonates
Treatment with BPs is able to prevent bone loss in men on 
ADT. However, most studies evaluated the ability of dif-
ferent BPs in preventing BMD decline, but they were not 
powered to evaluate fracture risk reduction [180–182].
Zoledronate was able to increase BMD in men with or 
without bone metastases treated with ADT [183, 184].
In a phase 3 double-blind placebo-controlled RCT 
on men treated with ADT, oral once-weekly 70 mg alen-
dronate increased both LS and TH BMD [185].
Oral risedronate significantly recovered BMD for up to 
24 months compared with the control group after starting 
ADT [186].
In an open-label study, IV pamidronate prevented hip 
and LS bone loss in men treated with ADT [187].
Finally, also neridronate prevented ADT-induced bone 
loss in a small RCT in patients with prostate cancer [188].
Denosumab
Denosumab has been approved for prevention of treatment-
related fragility fractures in men on ADT. In a double-blind 
multicenter placebo-controlled trial, denosumab (60 mg q 
6 months) determined a significant reduction of new ver-
tebral fractures incidence at 36 months and an increase of 
BMD at all skeletal sites [174].
SERMs
SERMs are effective in ameliorating BMD and reducing 
fracture risk in men on ADT, but they are not approved 
for this use probably due to a poor risk/benefit ratio. 
Raloxifene treatment increased hip BMD in a 12-month 
open-label study in men on ADT [189]. In a phase 3 
double-blind placebo-controlled trial, toremifene both 
improved BMD at all skeletal sites and reduced the 
incidence of new morphometric and clinical vertebral 
fractures, but it also increased the rate of venous throm-
boembolic events [190].
Recommendations
We suggest that men on ADT perform mild endurance
exercise consistent with the overall clinical state
We suggest that men on ADT consume 1000–1200 mg
daily calcium, possibly from dietary sources, if dietary
calcium is insufficient
We suggest vitamin D supplementation in men on ADT
and low vitamin D plasma levels
We recommend alendronate or zoledronate treatment
and suggest risedronate, pamidronate or neridronate
treatment in men on ADT if they have a high risk of
fracture
We recommend denosumab treatment in men on ADT
We recommend against the use of SERMs for treating
men on ADT, as these drugs are not registered for this
indication
Premenopausal osteoporosis
Osteoporosis in premenopausal women is rare and it is usu-
ally due to other conditions or diseases or is of genetic ori-
gin (i.e. osteogenesis imperfecta, Marfan syndrome, Gauch-
er’s disease) [191–193]. The pathophysiology of idiopathic 
osteoporosis is not well understood. Pregnancy-associated 
osteoporosis is a rare idiopathic form of spinal osteoporosis 
or transient osteoporosis of the hip. Preexisting low BMD 
and high bone turnover rate both during pregnancy and lac-
tation may play an important pathophysiologic role [194].
Medical history, physical examination and laboratory tests 
should be performed to detect secondary causes of osteoporo-
sis (table II in supplemental material). History of low trauma 
fractures is diagnostic for osteoporosis, but it is extremely 
rare in premenopausal females. The diagnosis of osteoporosis 
can be made even without fracture history, if a low BMD and 
a secondary cause of osteoporosis are both present.
The 2007 International Society for Clinical Densitom-
etry Official Position recommends the use of BMD Z-score 
instead of T-score in premenopausal women. For Z-score 
values <−2.0 a definition of “BMD below the expected 
range for age” should be used [195]. However, low BMD 
alone does not represent a pathological state [196] and it is 
not sufficient to diagnose osteoporosis since relationships 
between BMD and fracture incidence have not been estab-
lished in premenopausal women [197–199].
Finally, it should be reminded that fracture prediction 
tools such as the FRAX® are not applicable in subjects 
younger than 40 years.
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In case of secondary osteoporosis the first therapeutic 
approach should be addressed toward the removal or the 
management of the underlying cause (i.e. parathyroidec-
tomy for primary hyperparathyroidism, gluten free diet for 
celiac disease, nutritional rehabilitation and weight gain for 
nervous anorexia).
When a “BMD below the expected range for age” is 
diagnosed, behavioral advices are mandatory. Weight-bear-
ing exercise, adequate intake of calcium and vitamin D, 
smoking cessation and avoidance of excess alcohol are sug-
gested, albeit no evidence is available on their real effect in 
reducing fracture rate [200].
BPs are the most studied drugs and they may be pre-
scribed in the treatment of premenopausal osteoporosis, 
particularly in presence of fragility fractures. Anti-fracture 
efficacy of BPs has not been sufficiently documented in 
this setting, except for neridronate, pamidronate and rise-
dronate in osteogenesis imperfecta [201–203]. More posi-
tive results have been obtained when BMD increase was 
considered as an endpoint of BP treatment in some condi-
tions (i.e. inflammatory bowel diseases, nervous anorexia, 
cystic fibrosis, beta-thalassemia, osteogenesis imper-
fecta, Gaucher’s disease), even though these studies have 
both small size and short duration (usually <24 months) 
[201–209].
The most frequent form of secondary osteoporosis that 
might require treatment in premenopausal women is GIO. 
Patients taking 7.5 mg of daily glucocorticoids for more 
than 3 months with a prior history of fracture should be 
treated with BPs. Teriparatide should be used in patients 
with a higher risk of fracture or in those whose response to 
treatment is considered inadequate [210].
BPs administration during pregnancy could potentially 
lead to congenital malformations, [211–213]. Since BPs 
accumulate and remain for years in the skeleton, precaution 
is advised for their use before pregnancy and during lacta-
tion [214, 215].
Recommendations
We suggest using behavioral advices in premenopausal
women with low bone mass
We suggest using BPs (alendronate, neridronate,
pamidronate, risedronate, zoledronate) in
premenopausal women with fragility fractures and
primary or secondary osteoporosis
We suggest using BPs (alendronate, risedronate,
zoledronate) in premenopausal women with GIO and
fragility fractures
We suggest using teriparatide in premenopausal women
with GIO and fragility fractures after BPs failure
Aromatase inhibitors
Premature ovarian suppression induced by GnRH ago-
nists, chemotherapy, surgical removal, or irradiation is the 
first cause of bone damage in premenopausal women with 
BC, with an estimated bone loss of about 8 % within the 
first year [216]. In addition, both in pre- and postmenopau-
sal women, AI can decrease BMD and increase fragility 
fracture incidence compared to tamoxifen [217–220]. In 
a study comparing anastrozole with tamoxifen the overall 
incidence of fractures was higher in the former group (11.0 
vs. 7.7 %; OR 1.49; 95 % CI 1.25–1.77) [221].
The extent of bone loss is different for the various mol-
ecules at LS or TH, reaching a 5-year reduction for anastro-
zole of −6.1 and −7.2 %, respectively [218]. Letrozole and 
exemestane can induce a 2-year reduction in BMD by −5.3 
and −2.4 % at LS, respectively, whereas the respective fig-
ures were −3.6 and −1.8 % at TH [222, 223]. Over 30 % 
of the patients starting on anastrozole will have a diagnosis 
of osteoporosis in the subsequent years [218].
Several RCTs indicate that both oral and IV BPs as well 
as denosumab have protecting effects on BMD in this set-
ting. Zoledronate has shown a higher efficacy than oral 
BPs. In premenopausal women on anastrozole plus goser-
elin therapy the concomitant use of zoledronate (4 mg IV 
every 6 months) was able to improve BMD at 5 years, com-
pared to the group treated only with tamoxifen plus goser-
elin [217].
The three “Zometa-Femara Adjuvant Synergy Trials” 
have compared the efficacy of zoledronate in postmeno-
pausal women receiving adjuvant letrozole. The patients 
were randomly assigned to immediate zoledronate (4 mg 
IV q 6 months for 5 years), or zoledronate therapy start-
ing after a decrease in BMD or a non-traumatic fracture. 
At 60 months patients in the immediate group showed a 
LS and TH BMD gain of +4.3 and +1.6 %, respectively, 
while the respective figures in the delayed group were 
−5.4 and −4.2 %. Also the patients with a normal base-
line BMD (T-score >−1) showed a substantial decrease in 
LS (−7.1 %) if they were enrolled in the delayed group, 
while the immediate group achieved a 3.9 % increase [224–
226]. Similar results were obtained in a fourth study, where 
patients had previously been treated with tamoxifen for 
6 years and were then switched to letrozole [227].
Oral risedronate (35 mg weekly) given to postmenopau-
sal BC women treated with anastrozole increased BMD 
at 24 months (+2.2 to 5.7 % at LS and +1.6 to 1.8 % at 
TH) [228, 229]. In osteopenic postmenopausal women 
given anastrozole, patients treated with risedronate gained 
+1.1 % BMD at LS compared with a 2.6 % decrease in 
those without BP [230].
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In patients treated with anastrozole or letrozole, alen-
dronate significantly increased LS BMD by 3 % after a 
6-month treatment [231]. Finally in the 24-month Arimi-
dex–Ibandronate study, monthly 150 mg oral ibandronate 
prevented bone loss in osteopenic women and in a small 
number of women with PMO [232].
Although all studies on BPs were not designed for 
fracture incidence, a recent meta-analysis found that zole-
dronate (4 mg q 6 months) reduced significantly the overall 
fracture rate (OR 0.78; 95 % CI 0.63–0.96) [233].
Denosumab, 60 mg q 6 months SC for 24 months in 
postmenopausal women with low bone mass, was associ-
ated with larger BMD gains than placebo across multiple 
skeletal sites regardless of patient subgroups (prior tamox-
ifen use, duration and type of AI, time since menopause) 
[234, 235]. Denosumab reduced the risk of vertebral frac-
tures after 36 months of treatment compared to placebo 
[236].
On the basis of the AI effects on bone loss and fracture 
risk, BMD should be measured before AI treatment or 
within 6 months from treatment start and known risk fac-
tors for fracture (table I in supplemental material) should 
be explored.
Treatment should be initiated in the presence of a fra-
gility fracture irrespectively of BMD values, as well as in 
case of a baseline T-score <−2.0 SD, or if the annual rate 
of bone loss results >4 % at LS or TH, or in women com-
bining a T-score <−1.0 SD with more than one of the risk 
factors for fracture, and finally in women >65 years regard-
less of BMD [237–240].
In AI-treated patients the adverse event rates were simi-
lar to those described in the studies on primary osteoporo-
sis, both for BPs and denosumab. The optimal duration of 
treatment has not been established but is reasonable to con-
tinue anti-resorptives until AI treatment is ongoing.
Recommendations
We suggest that measuring BMD before starting AI
treatment is not strictly necessary
We recommend exploring known risk factors for fracture
and correcting modifiable factors
We recommend using oral BPs (risedronate, ibandronate,
alendronate) or IV zoledronate, or SC denosumab to
prevent bone loss in women treated with AI
We recommend using IV zoledronate or SC denosumab
and suggest using oral BPs (risedronate, ibandronate,
alendronate) to reduce fracture risk in women treated
with AI
We recommend continuing anti-resorptive treatment
possibly as long as AI therapy
Conclusions
Removal of modifiable risk factors as well as calcium and 
vitamin D levels optimization is a pre-requisite for any phar-
macological strategy for osteoporosis treatment. An appro-
priate screening of secondary forms of osteoporosis is man-
datory in the appropriate clinical setting. Start of treatments 
known to be detrimental to bone health, namely glucocorti-
coids, ADT and AI, should prompt a comprehensive treat-
ment plan to preserve bone health or minimize the damage.
Several drugs are available for the treatment of PMO. 
Almost all demonstrated a high anti-fracture efficacy 
together with a good safety profile, leading to a positive 
risk/benefit balance. Whereas most have proven to signifi-
cantly reduce the occurrence of vertebral fractures, some 
discrepancies remain regarding the level of evidence related 
to their non-vertebral or hip anti-fracture effect.
HT is no longer indicated for the management of PMO, 
but it might be considered for a limited length of time in the 
early postmenopausal woman with climacteric symptoms, 
with a careful individual evaluation of risk–benefit ratio.
SERMs might be a first-line option in early, asympto-
matic, postmenopausal women, but could be also consid-
ered in women <65 years at high risk of vertebral fractures.
BP administration represents an effective choice in post-
menopausal women >65 years at risk of vertebral fractures. 
Alendronate and risedronate could also be considered in 
women with established osteoporosis and high risk of hip 
fractures. Oral administration should be avoided in patients 
with delayed esophageal emptying and in those who are 
unable to maintain an upright position. These patients, and 
those with gastrointestinal adverse events, are candidates 
for IV zoledronate. Treatment can be continued for up to 
5 years; the use for a longer period should be considered 
with caution. A drug holiday has been suggested because 
of the persistent anti-fracture efficacy of these drugs after 
withdrawal, but treatment can be continued in those with 
very high risk of fracture.
Denosumab might be the first choice in patients with 
renal failure and high risk of fractures, and after failure or 
adverse events of other treatments. Hypocalcemia must be 
corrected prior to denosumab administration, particularly 
in patients with severely impaired renal function. Patients 
should be monitored for the risk of infections.
Because of the intermittent administration, zoledronate 
(once a year) and denosumab (every 6 months) may be an 
attractive option for patients with low adherence to drugs.
The use of SrR should be restricted to patients with 
severe osteoporosis, who are intolerant to other treatments, 
provided that there is no history of prior or concomitant 
cerebral or cardiovascular diseases.
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Treatment with teriparatide should be reserved to estab-
lished osteoporosis when prior therapies have failed and 
may be started soon after prior treatment withdrawal. Teri-
paratide should not be used in patients with hypercalcemia, 
neoplastic and metabolic bone diseases other than osteo-
porosis and should not be extended over 24 months. Anti-
resorptive therapy (BPs or denosumab) should be started 
upon termination of teriparatide to maintain its beneficial 
effects.
In conclusions, most women with PMO may need long-
term treatment and the sequential use of different drugs. 
An individualized approach should be defined when treat-
ment is started taking into account the fracture risk, the 
efficacy, safety, convenience and life expectancy. Phar-
macoeconomic issues and country-specific rules may 
influence the therapeutic strategy. The treating physician 
should choose the most suitable treatment for the individ-
ual patient based on medical history, fracture risk, drugs 
anti-fracture efficacy, presence of co-morbidities, previous 
treatment for osteoporosis, and preference of individual 
patients. Figure depicts a flowchart for the management of 
osteoporosis.
* No safety data for use in pregnancy. Always consider contraception.
# Always consider testosterone substitution in hypogonadal men.
Patients with 
osteoporosis
Pre-menopausal 
women* 
with 
fracture
Alendronate
Risedronate
Zoledronate
More severe forms:
Teriparatide
without 
fracture
Calcium
Vitamina D
Weight-bearing exercise
Smoking cessation
No alcohol excess
Post-menopausal 
women 
with 
fracture
Alendronate
Risedronate
Zoledronate
Denosumab
Second choice:
Ibandronate
Raloxifene
Bazedoxifene
More severe forms:
Teriparatide
Contraidication to all the 
others:
Strontium ranelate
or
Clodronate
without 
fracture
Alendronate
Risedronate
Zoledronate
Denosumab
Ibandronate
Raloxifene
Bazedoxifene
Contraidication to all the 
others:
Strontium ranelate
Men#
with 
fracture
Zoledronate
Alendronate
Risedronate
Denosumab
More severe forms:
Teriparatide
Contraidication to all the 
others:
Strontium ranelate
or
Clodronate
without 
fracture
Alendronate
Risedronate
Zoledronate
Denosumab
Contraidication to all the 
others:
Strontium ranelate
or
Clodronate
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